Literature DB >> 11072115

Gene therapy of chronic inflammatory disease.

M L Hedley1.   

Abstract

Immune mediated inflammation that culminates in severe tissue necrosis is the hallmark of diseases that result from an inappropriate response to antigen. The inflammatory response becomes chronic when antigen is non-limiting and persists until the reactive tissue is destroyed, or the environment is changed and exposure to antigen is eliminated. The purpose of this review is to: (1) briefly outline common features of immune related inflammatory diseases such as rheumatoid arthritis (RA), multiple sclerosis (MS), inflammatory bowel disease (IBD), and allergic asthma; (2) provide a rationale for the development of gene based drugs for these indications; and (3) describe current experimental results that support the usefulness of this approach for creating novel DNA based therapeutics.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11072115     DOI: 10.1016/s0169-409x(00)00095-8

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  4 in total

1.  Effects of cytokine gene therapy on particulate-induced inflammation in the murine air pouch.

Authors:  S Sud; S Y Yang; C H Evans; P D Robbins; P H Wooley
Journal:  Inflammation       Date:  2001-12       Impact factor: 4.092

Review 2.  Gene therapy in the treatment of intestinal inflammation.

Authors:  Catherine van Montfrans; Anje A te Velde; Sander J H van Deventer; Maria Sol Rodriguez Pena
Journal:  Int J Colorectal Dis       Date:  2003-06-25       Impact factor: 2.571

Review 3.  Steroid response in refractory asthmatics.

Authors:  An-Soo Jang
Journal:  Korean J Intern Med       Date:  2012-05-31       Impact factor: 2.884

4.  In vivo mucosal delivery of bioactive human interleukin 1 receptor antagonist produced by Streptococcus gordonii.

Authors:  Susanna Ricci; Giovanni Macchia; Paolo Ruggiero; Tiziana Maggi; Paola Bossù; Li Xu; Donata Medaglini; Aldo Tagliabue; Lennart Hammarström; Gianni Pozzi; Diana Boraschi
Journal:  BMC Biotechnol       Date:  2003-09-17       Impact factor: 2.563

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.